Type 2 Diabetes | Patient Profiler | US | 2018
Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second-line treatment options, including the DPP-IV inhibitors Januvia and Tradjenta, the SGLT-2 inhibitors Jardiance, Invokana, and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Optimized drug treatment can improve glycemic control, which can decrease the risk of specific comorbid conditions in T2D, including vascular and hepatic sequelae. In an increasingly competitive and congested market, brand differentiation and understanding of patient characteristics are ever more critical for marketers.
Questions Answered
- What is the patient share in type 2 diabetes for metformin, sulfonylureas, Novo Nordisk’s Victoza, and Sanofi’s Lantus?
- What are the demographic characteristics and clinical profiles of type 2 diabetes patients on SGLT-2 inhibitors or DPP-IV inhibitors?
- What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for type 2 diabetes?
- How do patient cohorts for type 2 diabetes compare in care utilization and outcomes (physician visits and other healthcare encounters)?
- What insurance type and provider do type 2 diabetes patients have?
- What are the reimbursed and out-of-pocket costs?
Product Description
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced using DRG’s comprehensive real-world data repository.
Markets Covered
United States
Research
Type 2 Diabetes Patient Profiler sources demographic, clinical, and cost-based metrics using DRG’s real-world data repository.
Key Companies
Boehringer Ingelheim, Janssen, Eli Lilly, Merck & Co., Novo Nordisk, and Sanofi.
Key Drugs
Biguanides, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, NovoLog, premixed insulin, sulfonylureas, Tradjenta, Toujeo, Trulicity, and Victoza.
